ClinicalTrials.gg

Program

formoterol

Also written as “Formoterol Fumarate”, “budesonide/formoterol” and “Formoterol”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic · Asthma, Exercise-Induced, led by 18 companies.

Furthest: phase 4, since Jan 4, 2006137 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca632 open or runningphase 4since Jan 4, 2006Sep 13, 2005May 31, 2027phase 4 · NCT07073950
Chiesi Farmaceutici200 open or runningphase 4since Nov 29, 2010Oct 30, 2006none ahead
Viatris160 open or runningphase 4since Nov 29, 2011Sep 13, 2005none ahead
Novartis60 open or runningphase 4since Jul 26, 2005Jul 26, 2005none ahead
Sumitomo Pharma60 open or runningphase 4since Jan 17, 2007Jul 8, 2003none ahead
SkyePharma50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratorios30 open or runningphase 3since Oct 23, 2009Oct 23, 2009none ahead
Mundipharma30 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
Ache Laboratorios Farmaceuticos20 open or runningphase 3since Mar 9, 2011Mar 9, 2011none ahead
Boehringer Ingelheim20 open or runningphase 2since Sep 11, 2014Sep 11, 2014none ahead
intech-biopharm-ltd20 open or runningphase 1since Jul 25, 2016Jul 25, 2016none ahead
Orion Corporation, Orion Pharma20 open or runningphase 2since Aug 24, 2009Aug 24, 2009none ahead
Zambon SpA20 open or runningphase 1since Sep 2, 2014Sep 2, 2014none ahead
Chenpon Pharmaceutical10 open or runningphase 3since Aug 24, 2026Aug 24, 2026none ahead
kindeva-drug-delivery10 open or runningphase 3since Jan 6, 2017Jan 6, 2017none ahead
Merck10 open or runningphase 4since Aug 30, 2005Aug 30, 2005none ahead
neutec-ar-ge-san-ve-tic-a-s10 open or runningphase 4since Oct 6, 2016Oct 6, 2016none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since Jul 1, 2015Jul 1, 2015none ahead

Also a collaborator on its studies: parexel, ciscrp, eresearchtechnology, Menarini Group, integrated-therapeutics-group and Pacira BioSciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Mar 9, 2011.

  1. Aug 23, 2017Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT03268226 · 20 enrolled · Belgium, Hungary
  2. Nov 10, 2017Phase 3 study in AsthmaMundipharma · NCT03387241 · 330 enrolled · China
  3. Sep 24, 2018Phase 3 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT03836677 · 23 enrolled · Belgium, Netherlands
  4. Jul 28, 2020Phase 1 study in Asthmaintech-biopharm-ltd · NCT04494321 · 99 enrolled · Taiwan
  5. Oct 26, 20202 phase 3 studies in AsthmaAstraZeneca · NCT04609904, NCT04609878
  6. May 3, 2021Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT04876677 · 25 enrolled · Belgium, Hungary
  7. Jan 10, 2022Phase 3 study in AsthmaAstraZeneca · NCT05202262 · 645 enrolled · United States, Canada, Germany and more
  8. Mar 4, 2022Phase 3 study in AsthmaChiesi Farmaceutici · NCT05292586 · 1,377 enrolled · United States
  9. Feb 23, 2023Phase 3 study in AsthmaAstraZeneca · NCT05755906 · 374 enrolled · United States, Canada, Czechia and more
  10. Sep 28, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06067828 · 171 enrolled · United States, Canada, China and more
  11. Feb 21, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06283966 · 5,250 planned · United States, Argentina, Australia and more
  12. Jul 17, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT07073950 · 56 planned · Germany, United Kingdom
  13. Feb 20, 2026Phase 1 study in AsthmaAstraZeneca · NCT07433569 · 16 enrolled · United States
  14. Aug 24, 2026Chenpon Pharmaceutical's first study: phase 3 study in AsthmaNew to Chenpon PharmaceuticalChenpon Pharmaceutical · NCT07790159 · 338 enrolled · China

Ahead

  1. May 31, 2027Primary completion: phase 4 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT07073950
  2. Dec 3, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06283966

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The newest 60 of 137 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07790159Asthma · China3CompletedChenpon PharmaceuticalSep 27, 2024338
NCT07433569Asthma · United States1CompletedAstraZenecaJun 26, 202616
NCT07073950Pulmonary Disease, Chronic Obstructive · Germany, United Kingdom4RecruitingAstraZenecaMay 31, 202756
NCT06283966Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3RecruitingAstraZenecaDec 3, 20275,250
NCT06067828Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more3CompletedAstraZenecaJan 22, 2026171
NCT05755906Asthma · United States, Canada, Czechia and more3CompletedAstraZenecaNov 19, 2024374
NCT05292586Asthma · United States3CompletedChiesi FarmaceuticiJun 24, 20241,377
NCT05202262Asthma · United States, Canada, Germany and more3CompletedAstraZenecaFeb 26, 2025645
NCT04876677Pulmonary Disease, Chronic Obstructive · Belgium, Hungary3CompletedChiesi FarmaceuticiJan 3, 202225
NCT04609904Asthma · United States, Brazil, China and more3CompletedAstraZenecaMar 20, 20252,187
NCT04609878Asthma · United States, Argentina, Belgium and more3CompletedAstraZenecaMar 21, 20252,274
NCT04494321Asthma · Taiwan1Completedintech-biopharm-ltdNov 17, 201799
NCT03836677Pulmonary Disease, Chronic Obstructive · Belgium, Netherlands3CompletedAstraZenecaNov 11, 201923
NCT03387241Asthma · China3UNKNOWNMundipharmaDec 30, 2019330
NCT03268226Pulmonary Disease, Chronic Obstructive · Belgium, Hungary3CompletedChiesi FarmaceuticiJan 30, 201920
NCT03162055Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Canada and more3CompletedAstraZenecaMay 4, 20181,119
NCT03181880Pulmonary Disease, Chronic Obstructive4WithdrawnAstraZenecaDec 3, 20180
NCT03022097Pulmonary Disease, Chronic Obstructive · China, India, Philippines and more3CompletedAstraZenecaApr 14, 20221,625
NCT03015259Asthma · United States3Completedkindeva-drug-deliveryFeb 8, 20181,762
NCT02975843Pulmonary Disease, Chronic Obstructive1CompletedChiesi FarmaceuticiMar 21, 201728
NCT02988869Pulmonary Disease, Chronic Obstructive · Turkey4Completedneutec-ar-ge-san-ve-tic-a-sAug 201784
NCT02850484Asthma1Completedintech-biopharm-ltdMay 201699
NCT02796651Pulmonary Disease, Chronic Obstructive · United States2CompletedAstraZenecaDec 7, 2016132
NCT02796677Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Czechia and more3CompletedAstraZenecaJun 8, 20171,595
NCT02766608Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more3CompletedAstraZenecaDec 1, 20172,389
NCT03262012Pulmonary Disease, Chronic Obstructive · Japan3CompletedAstraZenecaJun 15, 2018416
NCT03073057Asthma · Finland1CompletedOrion Corporation, Orion PharmaMar 201620
NCT02685293Pulmonary Disease, Chronic Obstructive · United States3TerminatedAstraZenecaJun 6, 20184
NCT02631941Asthma · United Kingdom1CompletedZambon SpAJul 201691
NCT02536508Pulmonary Disease, Chronic Obstructive · United States3CompletedAstraZenecaSep 12, 2017627
NCT02497001Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more3CompletedAstraZenecaJan 5, 20181,902
NCT02495168Asthma · United States3CompletedTeva Pharmaceutical IndustriesMay 31, 20181,714
NCT02491970Asthma4TerminatedMundipharmaApr 6, 201715
NCT02465567Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedAstraZenecaJul 26, 20198,588
NCT02424344Pulmonary Disease, Chronic Obstructive · Canada, Germany, Hungary and more4CompletedAstraZenecaJul 25, 2016267
NCT02347085Pulmonary Disease, Chronic Obstructive3CompletedAstraZenecaJun 1, 201543
NCT02347072Pulmonary Disease, Chronic Obstructive3CompletedAstraZenecaAug 1, 201580
NCT02343458Pulmonary Disease, Chronic Obstructive · United States, China, Czechia and more3CompletedAstraZenecaAug 31, 20171,756
NCT02242240Pulmonary Disease, Chronic Obstructive2CompletedBoehringer IngelheimDec 200195
NCT02238119Pulmonary Disease, Chronic Obstructive2CompletedBoehringer IngelheimAug 200274
NCT02237508Asthma · United Kingdom1CompletedZambon SpAFeb 201590
NCT02196714Pulmonary Disease, Chronic Obstructive · United States1CompletedAstraZenecaSep 201424
NCT02196077Pulmonary Disease, Chronic Obstructive · United States2CompletedAstraZenecaMar 1, 2015180
NCT02189304Pulmonary Disease, Chronic Obstructive · United States1CompletedAstraZenecaSep 1, 201459
NCT02119234Pulmonary Disease, Chronic Obstructive · Poland1CompletedChiesi FarmaceuticiFeb 201536
NCT02040597Pulmonary Disease, Chronic Obstructive · Poland1CompletedChiesi FarmaceuticiApr 201542
NCT01917331Pulmonary Disease, Chronic Obstructive · Hungary3CompletedChiesi FarmaceuticiJan 14, 20161,368
NCT01908140Pulmonary Disease, Chronic Obstructive · Austria, Bulgaria, Canada and more3CompletedAstraZenecaAug 2014933
NCT01854658Pulmonary Disease, Chronic Obstructive · United States3CompletedAstraZenecaMar 20151,615
NCT01845025Asthma · United States4TerminatedNovartisMay 2016827
NCT01794780Pulmonary Disease, Chronic Obstructive · China4CompletedNovartisMay 25, 20152,229
NCT01676987Asthma3CompletedAche Laboratorios FarmaceuticosSep 2010181
NCT01658891Asthma in Children · Denmark3WithdrawnChiesi FarmaceuticiNov 20150
NCT01641081Asthma · United States2CompletedAstraZenecaFeb 2013174
NCT01584492Asthma · Poland, Ukraine2CompletedChiesi FarmaceuticiFeb 201359
NCT01551888Pulmonary Disease, Chronic Obstructive · United States2CompletedAstraZenecaMar 201224
NCT01488019Pulmonary Disease, Chronic Obstructive · United States4CompletedViatrisJan 20161,071
NCT01475032Asthma · Bulgaria, France, Germany and more3CompletedChiesi FarmaceuticiSep 2012638
NCT01398111Pulmonary Disease, Chronic Obstructive · Belgium1CompletedChiesi FarmaceuticiAug 201144
NCT01393145Pulmonary Disease, Chronic Obstructive3WithdrawnAche Laboratorios FarmaceuticosAug 20120

How it is read

Names in the registry

  • “Formoterol Fumarate”, 14 entries
  • “budesonide/formoterol”, 10 entries
  • “Formoterol”, 9 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “BGF MDI 320/14.4/9.6 μg”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.